Does anti-TNF therapy influence the performance of mycobacterium tuberculosis antigen-specific interferon-gamma assays? A French multicenter experience
✍ Scribed by E. Del Tedesco; X. Roblin; D. Laharie; L. Peyrin Biroulet
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 42 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
✦ Synopsis
We read with great interest the article by Qumseya et al. reporting the results of QuantiFERON tuberculosis gold (QFT-G) testing for tuberculosis screening in an inflammatory bowel disease (IBD) cohort in the United States. 1 Among 340 patients who were tested with QFT-G test, the authors found that concomitant use of immunosuppressive therapy (n ¼ 136) or antitumor necrosis factor (TNF) (n ¼ 198) did not affect QFT-G results. 1 Herein we report the results of a French multicenter prospective study comparing tuberculin skin tests (TSTs) and interferon-gamma release assays (IGRAs) in 93 IBD patients. 2 In this IBD cohort (mean age 40.3 years), concordance between the two tests was poor (j ¼ 0.218; 95% confidence interval [CI] À0.118-0.554). Importantly,